Dual GLP-1/Glucagon Peptide Cotadutide Protects Kidneys in Diabetic Kidney Disease Trial
Cotadutide, a dual GLP-1/glucagon receptor agonist, dose-dependently reduced urine albumin by up to 50% in 248 patients with diabetic kidney disease, with safety comparable to semaglutide.
Quick Facts
What This Study Found
Cotadutide dose-dependently reduced UACR at week 14: 300 μg (-43.9%, CI -54.7 to -30.6) and 600 μg (-49.9%, CI -59.3 to -38.4) vs placebo. Effects sustained at 26 weeks. Safety of cotadutide 600 μg comparable to semaglutide. Serious AEs balanced across arms. 46.8% on concomitant SGLT2i.
Key Numbers
Patients with eGFR 20-90 mL/min/1.73m² and UACR >50 mg/g. 26-week treatment. 1:1:1:1:1 randomization.
How They Did This
Phase 2b, randomized, double-blind (cotadutide vs placebo), open-label (semaglutide) trial. 248 patients with T2D and CKD (eGFR 20-90, UACR >50 mg/g) randomized 1:1:1:1:1 to cotadutide 100, 300, or 600 μg daily, placebo daily, or semaglutide 1 mg weekly for 26 weeks. Co-primary endpoints: absolute and percentage UACR change from baseline to week 14.
Why This Research Matters
Diabetic kidney disease is the leading cause of kidney failure worldwide. While GLP-1 agonists and SGLT2 inhibitors offer some kidney protection, cotadutide's dual mechanism (adding glucagon receptor activation) produced nearly 50% albuminuria reduction — potentially a more powerful kidney-protective approach for high-risk patients.
The Bigger Picture
This adds cotadutide to the growing list of peptide-based drugs showing kidney protection in diabetes. The near-50% UACR reduction on top of standard care (including SGLT2i in nearly half) suggests additive kidney protection from targeting multiple metabolic pathways simultaneously.
What This Study Doesn't Tell Us
Phase 2b — not powered for hard kidney endpoints (progression to dialysis, eGFR decline). UACR is a surrogate marker. Open-label semaglutide arm may introduce bias. 26-week duration may not reflect long-term kidney protection. Cotadutide requires daily injection vs semaglutide's weekly dosing.
Questions This Raises
- ?Will cotadutide's UACR reduction translate to fewer patients progressing to kidney failure in larger, longer trials?
- ?How does cotadutide compare head-to-head with semaglutide for kidney protection?
- ?Would combining cotadutide with SGLT2i provide even greater kidney protection than either alone?
Trust & Context
- Key Stat:
- -49.9% UACR Cotadutide 600 μg reduced the kidney damage marker UACR by nearly 50% in diabetic kidney disease patients, on top of standard care including SGLT2 inhibitors
- Evidence Grade:
- Rated moderate: well-designed phase 2b RCT with adequate sample size for signal detection, but UACR is a surrogate endpoint and the study wasn't powered for hard kidney outcomes.
- Study Age:
- Published in 2024 in Kidney International. Provides key data for designing phase 3 trials of cotadutide in diabetic kidney disease.
- Original Title:
- A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
- Published In:
- Kidney international, 106(6), 1170-1180 (2024)
- Authors:
- Selvarajah, Viknesh, Robertson, Darren, Hansen, Lars(2), Jermutus, Lutz, Smith, Kirsten, Coggi, Angela, Sánchez, José, Chang, Yi-Ting, Yu, Hongtao, Parkinson, Joanna, Khan, Anis, Chung, H Sophia, Hess, Sonja, Dumas, Richard, Duck, Tabbatha, Jolly, Simran, Elliott, Tom G, Baker, John, Lecube, Albert, Derwahl, Karl-Michael, Scott, Russell, Morales, Cristobal, Peters, Carl, Goldenberg, Ronald, Parker, Victoria E R, Heerspink, Hiddo J L
- Database ID:
- RPEP-09235
Evidence Hierarchy
Frequently Asked Questions
Can peptide drugs protect the kidneys in diabetes?
Yes — this trial showed cotadutide (a dual GLP-1/glucagon peptide) reduced a key kidney damage marker by nearly 50% in diabetic patients with kidney disease. It works on top of existing treatments including SGLT2 inhibitors.
What is cotadutide and how is it different from semaglutide?
Cotadutide activates both GLP-1 and glucagon receptors, while semaglutide only activates GLP-1 receptors. This dual action may provide additional metabolic and kidney-protective benefits, though cotadutide currently requires daily injection vs semaglutide's weekly dosing.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09235APA
Selvarajah, Viknesh; Robertson, Darren; Hansen, Lars; Jermutus, Lutz; Smith, Kirsten; Coggi, Angela; Sánchez, José; Chang, Yi-Ting; Yu, Hongtao; Parkinson, Joanna; Khan, Anis; Chung, H Sophia; Hess, Sonja; Dumas, Richard; Duck, Tabbatha; Jolly, Simran; Elliott, Tom G; Baker, John; Lecube, Albert; Derwahl, Karl-Michael; Scott, Russell; Morales, Cristobal; Peters, Carl; Goldenberg, Ronald; Parker, Victoria E R; Heerspink, Hiddo J L. (2024). A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.. Kidney international, 106(6), 1170-1180. https://doi.org/10.1016/j.kint.2024.08.023
MLA
Selvarajah, Viknesh, et al. "A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.." Kidney international, 2024. https://doi.org/10.1016/j.kint.2024.08.023
RethinkPeptides
RethinkPeptides Research Database. "A randomized phase 2b trial examined the effects of the gluc..." RPEP-09235. Retrieved from https://rethinkpeptides.com/research/selvarajah-2024-a-randomized-phase-2b
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.